Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638453 | 0.78 | CXCR4 (0.47) | LMNA | |
| SCHEMBL5795101 | 0.77 | ALDH1A1 (0.33) | TAAR1ADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL1637370 | 0.73 | TAAR1 (0.40) | TAAR1CYP2D6TSHRLMNAGLA | |
| SCHEMBL1638305 | 0.70 | AAK1 (0.33) | — | |
| SCHEMBL1206403 | 0.69 | ALDH1A1 (0.48) | ADRA2AADRA2BADRA2CSMN1; SMN2 | |
| SCHEMBL2693545 | 0.68 | CYP2D6 (0.36) | TAAR1ADRA2AADRA2BADRA2CCYP2D6 | |
| SCHEMBL6205526 | 0.63 | HDAC1 (0.50) | LMNASMN1; SMN2 | |
| SCHEMBL7819462 | 0.62 | CYP19A1 (0.39) | TAAR1LMNASMN1; SMN2 | |
| SCHEMBL2127047 | 0.62 | CYP2D6 (0.46) | TAAR1CYP2D6TSHRLMNAGLA | |
| SCHEMBL5597421 | 0.62 | FPR2 (0.39) | ADRA2AADRA2BADRA2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | TAAR1 67/4885ADRA2A 243/4885ADRA2B 179/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | TAAR1 82/4885ADRA2A 196/4885ADRA2B 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.